Zepbound coverage hinges on your insurance plan, and the landscape shifted dramatically in 2026. Most large employer plans cover Zepbound with prior authorization—about 43% of companies with 5,000 or more employees offer coverage—while Medicare Part D and most marketplace plans exclude it for weight loss.
Some plans dropped coverage in January 2026, while others require extensive documentation before approval.
Over 88% of patients with coverage face prior authorization requirements. Roughly 97 million Americans now have plans that exclude Zepbound after recent formulary changes.
Appeals succeed more than 65% of the time when patients submit proper documentation. The December 2024 FDA approval for obstructive sleep apnea opened a separate coverage pathway that works even when weight loss is excluded.
Whether you’re navigating prior authorization, weighing self-pay options, or checking your plan’s specifics, understanding the system is crucial. The right documentation can mean the difference between paying $1,000 per month and getting approved.
Is Zepbound Covered by Insurance?
Coverage for Zepbound depends on your plan type, employer size, and whether your insurer classifies it as a weight-loss medication or for alternative indications like sleep apnea. Most large employer plans offer some pathway to coverage, while Medicare and marketplace plans remain restrictive.
Key Factors That Affect Coverage
Plan type is the most important factor. Large employer plans—especially those covering 5,000 or more employees—approve Zepbound at rates near 43%.
Companies with 20,000+ workers push that figure to 64%. Small and mid-sized employer plans lag behind; only 19% of companies with 200-999 employees cover GLP-1 medications for weight loss.
Self-funded employer plans can add Zepbound coverage even if the carrier’s standard formulary excludes it. Medicare Part D excludes weight-loss drugs by federal statute, except for the obstructive sleep apnea indication approved in December 2024.
Medicaid coverage varies by state—13 states explicitly cover GLP-1s for obesity, though California restricted access starting January 1, 2026. Prior authorization affects more than 88% of patients with coverage.
Insurers typically demand BMI documentation, records of weight-related health conditions, and proof of lifestyle program participation before approval.
Current Insurance Landscape for 2026
The commercial insurance market tightened in early 2026. Health New England and Fallon Health dropped Wegovy, Zepbound, and Saxenda for individual and small group members effective January 1.
CVS Caremark removed Zepbound from its standard formulary in July 2025. An estimated 97 million Americans now belong to plans that exclude Zepbound after major pharmacy benefit manager removals.
ACA marketplace plans rarely cover obesity medications—fewer than 1% include them. The CMS BALANCE Model, launched December 2025, allows states to join a voluntary pilot starting May 2026.
Medicare beneficiaries may access GLP-1s at a fixed $50 monthly cost through a bridge demonstration beginning July 2026. About 90% of large employers currently covering GLP-1 medications plan to maintain that coverage through 2026, despite premium increases between 6-14%.
How Formulary Status Impacts Access
Drug formularies determine whether Zepbound appears on your plan’s approved medication list and at what tier. When insurers classify Zepbound as a weight-loss medication, they often place it on exclusion lists.
Formulary placement typically breaks down as:
- Tier 3 (Preferred brand): $50-75 copay after prior authorization
- Tier 4 (Non-preferred brand): $100-150 copay with stricter criteria
- Tier 5 (Specialty): 25-33% coinsurance, often $400-800 monthly
- Not covered: Excluded from formulary entirely
Your pharmacy benefit manager controls formulary decisions for your health plan. Formularies are updated quarterly or annually, so coverage can change between plan years.
The sleep apnea pathway creates a separate formulary entry. Plans that exclude weight-loss medications often cover the OSA indication because it treats a respiratory condition rather than obesity.
Eligibility Criteria for Zepbound Insurance Coverage
Insurance companies evaluate Zepbound coverage based on medical criteria, primarily your body mass index and documented health conditions. The approval process differs depending on whether you’re seeking treatment for weight management or obstructive sleep apnea.
BMI and Medical Necessity Requirements
Most insurers require a BMI of 30 or higher for Zepbound approval. If your BMI is 27-29.9, you’ll need at least one weight-related comorbidity documented.
These comorbidities include:
- Hypertension (high blood pressure)
- Type 2 diabetes or prediabetes
- High cholesterol or triglycerides
- Cardiovascular disease
- Non-alcoholic fatty liver disease (NAFLD)
- Polycystic ovary syndrome (PCOS)
Insurers also want evidence of previous weight loss attempts—usually 3-6 months of lifestyle modifications like diet and exercise. Some plans require proof you’ve tried and failed with other weight loss medications before Zepbound.
We’ve seen cases where a BMI of 32 was denied, while a BMI of 28 with documented sleep apnea was approved.
Indications: Weight Management vs. Obstructive Sleep Apnea
Zepbound carries two FDA-approved indications, and your approval odds shift depending on which applies.
For obesity management, insurers require BMI documentation plus evidence of previous weight loss attempts. Many plans exclude weight loss medications entirely from their formularies.
For obstructive sleep apnea (OSA), the pathway is typically easier. Zepbound received FDA approval for moderate to severe OSA in adults with obesity.
If you have a sleep study confirming OSA diagnosis, insurers may view this as a clearer medical necessity. The OSA indication requires a sleep study showing an apnea-hypopnea index (AHI) of 15 or higher.
Some plans also require that you’ve tried CPAP therapy first.
Typical Documentation Needed
Your healthcare provider must submit comprehensive documentation for prior authorization. Missing a required element can trigger an automatic denial.
Essential documents include:
- Recent BMI measurements (within the last 3 months)
- Complete medical history, including comorbid conditions
- Records of previous weight loss attempts with dates and outcomes
- Lab results showing metabolic markers
- Letter of medical necessity from your physician
- Sleep study results (if applying under OSA indication)
The letter of medical necessity should explain why Zepbound specifically addresses your needs and why other treatments haven’t worked. Insurers look for detailed, patient-specific justifications.
Some plans also require documentation of nutrition counseling or participation in a supervised weight management program. Gather all documentation before starting the prior authorization process.
Prior Authorization and Insurance Barriers
Insurance companies use prior authorization as a gatekeeping tool for Zepbound coverage. Most patients will encounter this requirement along with hurdles like step therapy protocols.
What Is Prior Authorization?
Prior authorization (PA) is a review process where your insurer decides if Zepbound meets their medical necessity standards before approving coverage. Your doctor submits documentation explaining why you need this specific medication.
Insurance companies and their pharmacy benefit managers (PBMs) examine your medical history, BMI, previous weight loss attempts, and related health conditions. They’re looking for evidence that Zepbound is appropriate and necessary.
Most PA requests take 72 hours to two weeks for a decision. During this period, you can’t fill your prescription at the covered rate.
Common PA Requirements for Zepbound
Insurers typically demand:
- BMI thresholds: Usually 30 or higher, or 27+ with comorbidities
- Failed weight loss attempts: 3-6 months of diet and exercise without adequate results
- Medical records: Detailed notes showing obesity impacts your health
- FDA-approved indications only: Coverage for chronic weight management, not off-label or cosmetic use
Your doctor must provide medical charts, progress notes, and lab results. PBMs often reject initial requests to push patients toward cheaper alternatives first.
Step Therapy and Alternative Medications
Step therapy protocols require you to try less expensive medications before Zepbound. This often means starting with older weight loss drugs or compounded versions.
Your insurer might require you to fail on metformin, phentermine, or other generics first. Each “step” typically involves 30-90 days of treatment with documented lack of effectiveness.
Some plans also require trying Wegovy or Saxenda before Zepbound.
Coverage by Insurance Plan Type
Zepbound coverage splits sharply across plan types. Large employer plans offer the strongest access, while government programs like Medicare remain restricted for weight loss—though the sleep apnea pathway and upcoming 2026 policy changes are shifting that landscape.
Employer-Sponsored and Commercial Plans
Large employer-sponsored plans offer the clearest coverage path. About 43% of companies with 5,000 or more employees cover GLP-1 medications like Zepbound for weight loss.
That number jumps to 64% among employers with 20,000+ workers. Smaller companies lag; only 19% of employers with 200-999 employees include weight-loss medication coverage.
Coverage typically requires:
- Prior authorization from your physician
- BMI of 30 or higher (or 27+ with weight-related conditions)
- Documentation of previous weight management attempts
- Proof of lifestyle modification programs
Major commercial insurers like Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna have inconsistent policies. Coverage depends on your specific plan design, not just the insurer’s name.
Self-funded employer plans have independent authority to include or exclude Zepbound regardless of the insurer’s standard formulary. CVSCaremark removed Zepbound from its standard formulary in July 2025, preferring Wegovy instead.
This affects millions, though self-funded employers can still negotiate separate terms. ACA marketplace plans rarely cover weight-loss medications; less than 1% include obesity drug coverage as of 2026.
Medicare and Medicare Advantage
Medicare Part D cannot cover Zepbound for weight loss due to federal statute. The sleep apnea pathway, however, changes the equation.
Since December 2024, Zepbound carries FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Medicare Part D plans can cover this indication with proper sleep study documentation.
Medicare Advantage plans follow the same federal restrictions but may offer supplemental benefits. Some include limited weight management programs, though comprehensive GLP-1 coverage remains uncommon.
The CMS BALANCE Model launches mid-2026 with a bridge demonstration program. Eligible Medicare beneficiaries may access GLP-1 medications at a fixed $50 monthly cost starting July 2026.
Full Medicare Part D expansion through BALANCE begins January 2027, though participation is voluntary for plans and manufacturers.
Medicaid State Programs
Medicaid coverage for GLP-1 medications varies widely by state. Thirteen states cover at least one GLP-1 for weight management under fee-for-service, while 36 states limit coverage to diabetes or other approved uses.
California Medi-Cal will restrict GLP-1 coverage for weight loss starting January 1, 2026. Exceptions remain for patients under 21, those with cardiovascular disease, and for sleep apnea.
The BALANCE Model could expand Medicaid access. States may join from May through December 2026 by submitting letters of intent to CMS, gaining access to negotiated pricing that may make coverage more sustainable.
Medicaid managed care plans often have stricter requirements than fee-for-service. Always verify coverage directly with your state Medicaid program, as policies change frequently.
TRICARE and Veterans Affairs
TRICARE does not cover Zepbound for weight loss under standard pharmacy benefits. Medications prescribed primarily for weight reduction are excluded unless treating another medical condition.
The sleep apnea indication may allow coverage for TRICARE beneficiaries with documented OSA, but prior authorization is required. Coverage decisions follow Department of Defense pharmacy policies.
Veterans Affairs (VA) operates its own formulary. The VA covers select GLP-1s for diabetes but generally excludes weight-loss prescriptions, though some medical centers may make exceptions for sleep apnea.
Active-duty service members face additional restrictions. Non-formulary drugs like Zepbound require exceptional approval through medical necessity reviews.
What to Do if Zepbound Coverage Is Denied
A denial is frustrating, but not final. Most insurers have appeals processes, and success rates exceed 65% when appeals include strong medical documentation and physician support.
Appealing an Insurance Denial
Start by requesting a written explanation from your insurer within 48 hours of the denial notice.
Common denial reasons include:
- Insufficient documentation of medical necessity
- Missing BMI or comorbidity records
- Incomplete prior weight loss attempt history
- Plan exclusions for weight management medications
Insurers typically allow 60 to 180 days to file an appeal. Check your plan’s deadline immediately. The appeals process usually involves an internal review, followed by an external review if necessary.
Denials due to incomplete documentation are often overturned when resubmitted with stronger evidence. Blanket exclusions for weight loss drugs are rarely reversed.
Evidence-Backed Appeal Letters
Effective appeal letters address the insurer’s reasons for denial with specific medical evidence. Your doctor should provide a detailed letter of medical necessity.
Essential components include:
- Current BMI with measurements over 6–12 months
- Diagnosed comorbidities (e.g., sleep apnea, hypertension)
- Previous weight loss attempts with dates and outcomes
- Rationale for Zepbound’s necessity
- Clinical trial data supporting tirzepatide’s efficacy
Attach lab results, sleep study findings, and specialist notes. Comprehensive documentation makes it harder for insurers to deny coverage.
Working With Your Doctor and Insurer
Physicians may deprioritize prior authorization paperwork. Make the process easier by preparing your weight history, current medications, and previous treatments in advance.
Obesity medicine specialists are often more experienced with these requests. Consider requesting a peer-to-peer review, where your doctor speaks directly with the insurer’s medical director to advocate for coverage.
Zepbound Savings Cards and Alternative Payment Options
Zepbound costs about $1,000 per month without assistance. Lilly USA offers savings programs that can lower out-of-pocket costs to as little as $25 for eligible commercially insured patients.
Manufacturer Savings Programs
The Zepbound Savings Card helps commercially insured patients pay as little as $25 per month, with maximum savings of $100 monthly and $1,300 annually. The card covers up to 13 prescription fills per year.
For those with commercial insurance that does not cover Zepbound, the card lowers costs to as little as $499 per month, with up to $620 in monthly savings.
Eligibility requirements:
- Must have commercial/private insurance
- Not enrolled in Medicare, Medicaid, VA, TRICARE, or government programs
- Must be 18+ and a U.S. resident
- Requires a valid prescription for FDA-approved uses
This is not insurance. The card expires December 31, 2026, and Lilly may change or end the program at any time.
Using GoodRx and Other Discount Programs
GoodRx and similar programs can offer some savings, but usually less than the manufacturer’s card. These platforms negotiate prices with pharmacies and pass savings to consumers.
The Zepbound Savings Card cannot be combined with other discount programs or coupons. For most commercially insured patients, the manufacturer’s program offers the best value.
LillyDirect and Self-Pay Options
LillyDirect is Lilly’s online pharmacy that ships medications directly to patients. This is a convenient option for self-pay patients or those without insurance coverage.
Zepbound vials through LillyDirect may cost less than retail pharmacy pens. The platform handles prescription, payment, and shipping, with discreet and temperature-controlled delivery.
This option works well for patients in coverage gaps or those preferring direct management. A valid prescription is required.
Understanding Zepbound’s Place in Obesity and OSA Treatment
Zepbound marks a shift in weight management and sleep apnea care. It targets hormone pathways to reduce appetite and body weight, which can improve sleep apnea symptoms.
How Zepbound Works (GLP-1 and Tirzepatide Basics)
Tirzepatide, Zepbound’s active ingredient, mimics two hormones: GLP-1 and GIP. This dual action distinguishes it from single-action GLP-1 drugs.
Zepbound slows stomach emptying and reduces appetite. It is administered as a once-weekly injection, starting at 2.5 mg and titrated up to 10 or 15 mg as tolerated.
Mounjaro, which contains the same molecule, is FDA-approved for type 2 diabetes. Some insurers treat these brands differently for coverage.
Role of Diet, Exercise, and Medical Necessity
Zepbound must be used alongside a reduced-calorie diet and increased physical activity, as required by FDA approval.
Insurers require documentation of lifestyle changes. Providers must confirm patients are actively working on diet and exercise, though a formal program isn’t always necessary.
Medical necessity documentation typically includes:
- Current BMI and weight
- Weight management history
- Obesity-related health conditions
- For OSA: sleep study showing AHI ≥15
- Provider attestation of diet and exercise counseling
Combining tirzepatide with lifestyle changes yields better outcomes, according to clinical trials.
Zepbound vs. Other Weight Management Medications
Insurers often require trying older, less expensive drugs before approving GLP-1s like Zepbound.
| Medication | Type | How It Works | Insurance Position |
|---|---|---|---|
| Phentermine | Appetite suppressant | Stimulates neurotransmitter release | Often required first-line |
| Qsymia | Combination | Phentermine + topiramate | Second-tier option |
| Saxenda | GLP-1 (liraglutide) | Daily injection, single receptor | Often required before Zepbound |
| Wegovy | GLP-1 (semaglutide) | Weekly injection, single receptor | Similar tier to Zepbound |
| Zepbound | Dual GLP-1/GIP | Weekly injection, dual receptors | Newest option |
Step therapy is common, but the OSA indication may allow patients to bypass these requirements.
Zepbound produced greater weight loss than single-action GLP-1s in trials, with participants losing 16–17% of body weight over 52 weeks.
Coverage policies vary. Some plans exclude weight loss drugs entirely, while others require strict prior authorization. The OSA indication may create a separate pathway for coverage.
Cost of Zepbound With and Without Insurance
Zepbound’s price depends on insurance and formulation. With commercial insurance and a savings card, patients typically pay $25 per month. Without coverage, costs range from $349 to over $1,000 monthly.
Out-of-Pocket Expectations
Commercially insured patients can access Zepbound pens for $25 per month using the manufacturer’s card. This applies to all pen doses from 2.5 mg to 15 mg.
Without insurance, Zepbound pens cost $1,086 per month for a 28-day supply. The price is the same regardless of dose.
LillyDirect offers vials at lower prices. A 5 mg vial is $499 per month, while a 2.5 mg vial is $349. Vials require a separate needle and syringe but offer significant savings.
Price Differences by Formulation
Pens are the most expensive option at $1,086 monthly when purchased without insurance.
LillyDirect vials provide more affordable alternatives:
- 2.5 mg vial: $349/month
- 5 mg vial: $499/month
- 7.5 mg to 15 mg vials: $499/month (with timely refills)
Refilling within 45 days maintains the $499 monthly rate. Miss the window and prices rise to $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg, and $1,049 for 15 mg doses.
Annual and Monthly Cost Estimates
Annual costs are calculated based on consistent monthly use. Insured patients with the savings card pay about $300 per year ($25 × 12 months) for pen formulations—a notably accessible price.
Uninsured patients encounter much higher expenses. The pen formulation costs approximately $13,032 annually at full retail price.
Patients using the 5 mg vial through LillyDirect’s self-pay program spend about $5,988 per year, provided they refill on time to keep the lower pricing tier.
For those paying out-of-pocket at higher doses without the refill discount, costs can soar. Annual spending may reach $12,588 for the 15 mg vial dose at regular pricing.